Zura Bio
Kate Dingwall currently serves as the Senior Vice President of Development Operations at Zura Bio Limited, a position held since March 2025. Prior to this role, Kate held multiple leadership positions at Adaptimmune, notably as Vice President of Clinical Development Operations and Vice President of Clinical Science and Operations from October 2020 to February 2025. Kate's experience also includes serving as Senior Director of Immuno-Oncology Program Management and Section Director of Oncology Program Management at AstraZeneca from November 2017 to October 2020.
This person is not in any teams
This person is not in any offices
Zura Bio
1 followers
Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), torudokimab (ZB-880), and ZB-168 with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders. Zura Bio is headquartered in Henderson, NV with team members in the UK and USA.